A new trading day began on Monday, with UroGen Pharma Ltd (NASDAQ: URGN) stock price down -1.65% from the previous day of trading, before settling in for the closing price of $12.73. URGN’s price has ranged from $10.60 to $20.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 13144.25% over the last five years. Meanwhile, its annual earnings per share averaged 2.14%. With a float of $38.20 million, this company’s outstanding shares have now reached $42.11 million.
The firm has a total of 201 workers. Let’s measure their productivity. In terms of profitability, gross margin is 89.87%, operating margin of -93.74%, and the pretax margin is -128.98%.
UroGen Pharma Ltd (URGN) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of UroGen Pharma Ltd is 9.30%, while institutional ownership is 97.99%. The most recent insider transaction that took place on Sep 09 ’24, was worth 11,236. In this transaction Chief Medical Officer of this company sold 859 shares at a rate of $13.08, taking the stock ownership to the 145,091 shares. Before that another transaction happened on Sep 09 ’24, when Company’s General Counsel sold 1,521 for $13.08, making the entire transaction worth $19,895. This insider now owns 25,226 shares in total.
UroGen Pharma Ltd (URGN) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 2.14% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
Here are UroGen Pharma Ltd’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.27, a number that is poised to hit -0.74 in the next quarter and is forecasted to reach -2.75 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
Analysing the last 5-days average volume posted by the [UroGen Pharma Ltd, URGN], we can find that recorded value of 0.92 million was better than the volume posted last year of 0.5 million. As of the previous 9 days, the stock’s Stochastic %D was 59.77%. Additionally, its Average True Range was 0.78.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 13.02%, which indicates a significant decrease from 52.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.96% in the past 14 days, which was lower than the 74.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.41, while its 200-day Moving Average is $14.94. Now, the first resistance to watch is $12.75. This is followed by the second major resistance level at $12.99. The third major resistance level sits at $13.15. If the price goes on to break the first support level at $12.35, it is likely to go to the next support level at $12.19. Should the price break the second support level, the third support level stands at $11.95.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
With a market capitalization of 527.22 million, the company has a total of 23,454K Shares Outstanding. Currently, annual sales are 82,710 K while annual income is -102,240 K. The company’s previous quarter sales were 21,850 K while its latest quarter income was -33,400 K.
